Claims

1. A compound of formula (I)



Formula (I)

pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof,

wherein X is selected from CH_2, CO, CHOH, CHO(C_1-C_3) alkyl, NH, and O;

wherein Y^1 is N and R^7 is absent, Y^2 is selected from N and C and Y^3 is C;

wherein Z is $NR^{10}R^{11}$, wherein R^{10} and R^{11} are each independently selected from H and C_1-C_6 alkyl;

wherein R^1 is selected from H, halogen, C_1-C_6 alkyl, C_3-C_{12} cycloalkyl, C_3-C_{12} heterocyclyl, C_1-C_6 alkoxy, C_1-C_6 heteroalkyl, C_0-C_3 alkylOC_0-C_3 alkyl aryl wherein the aryl is optionally substituted by NH_2, OC_1-C_6 alkyl, C_1-C_6 alkyl, C_1-C_6 heteroalkyl, halogen, CN, C_3-C_{12} cycloalkyl, C_3-C_{12} heterocyclyl; C_0-C_3 alkylOC_0-C_3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH_2, OC_1-C_6 alkyl, C_1-C_6 alkyl, C_1-C_6 heteroalkyl, halogen, CN, C_3-C_{12} cycloalkyl, C_3-C_{12} heterocyclyl; and C_1-C_6 alkyl substituted by aryl or heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH_2, OC_1-C_6 alkyl, C_1-C_6 alkyl, C_1-C_6 heteroalkyl, halogen, CN, C_3-C_{12} cycloalkyl, C_3-C_{12} heterocyclyl;

wherein R^2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH_2, OC_1-C_6 alkyl, C_1-C_6 alkyl, C_1-C_6 heteroalkyl, halogen, CN, C_3-C_{12} cycloalkyl, C_3-C_{12} heterocyclyl, $C(O)R^{12}$, C_1-C_6 alkyl $C(O)R^{12}$;

wherein R^3 is selected from H, halogen, C_1-C_6 alkyl and C_3-C_{12} cycloalkyl;

wherein R^4 is selected from H and halogen and R^5 and R^6 are each independently selected from H and C_1-C_6 alkyl;

wherein R^8 is selected from H, halogen, C_1-C_6 alkyl and C_3-C_{12} cycloalkyl;

wherein R^9 is absent when Y^2 is N or is selected from H, halogen, C_1-C_6 alkyl and C_3-C_{12} cycloalkyl when Y^2 is C; and

wherein R^{12} is selected from NH_2, NHC_1-C_6 alkyl, C_1-C_6 alkyl, and C_1-C_6 heteroalkyl

~~wherein X is selected from CH_2, CF_2, CHF, CO, CHOH, CHO(C_1-C_3) alkyl, NH, N(C_1-C_3 alkyl), S, SO and O;~~

~~wherein Y^1, Y^2, and Y^3 are each independently selected from N and C;~~

~~wherein Z is $NR^{10}R^{11}$, wherein R^{10} and R^{11} are each independently selected from H and C_1-C_6 alkyl;~~

~~wherein R^1 is selected from H, halogen, C_1-C_6 alkyl, C_3-C_{12} cycloalkyl, C_3-C_{12} heterocyclyl, C_1-C_6 alkoxy, C_1-C_6 heteroalkyl, C_0-C_3 alkylOC_0-C_3 alkyl aryl wherein the aryl is optionally substituted by NH_2, OC_1-C_6 alkyl, C_1-C_6 alkyl, C_1-C_6 heteroalkyl, halogen, CN, C_3-C_{12} cycloalkyl, C_3-C_{12} heterocyclyl; C_0-C_3 alkylOC_0-C_3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH_2, OC_1-C_6 alkyl, C_1-C_6 alkyl, C_1-C_6 heteroalkyl, halogen, CN, C_3-C_{12} cycloalkyl, C_3-C_{12} heterocyclyl; and C_1-C_6 alkyl substituted by aryl or heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH_2, OC_1-C_6 alkyl, C_1-C_6 alkyl, C_1-C_6 heteroalkyl, halogen, CN, C_3-C_{12} cycloalkyl, C_3-C_{12} heterocyclyl;~~

~~wherein R^2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH_2, OC_1-C_6 alkyl, C_1-C_6 alkyl, C_1-C_6 heteroalkyl, halogen, CN, C_3-C_{12} cycloalkyl, C_3-C_{12} heterocyclyl, $C(O)R^{12}$, C_1-C_6 alkyl $C(O)R^{12}$;~~

~~wherein R^3 is selected from H, halogen, C_1-C_6 alkyl, C_1-C_6 heteroalkyl, C_3-C_{12} cycloalkyl, C_3-C_{12} heterocyclyl and C_1-C_6 alkoxy;~~

~~wherein R^4, R^5 and R^6 are each independently selected from H, halogen, CN, C_1-C_6 alkoxy, C_1-C_6 S alkyl, C_1-C_6 alkyl, C_1-C_6 heteroalkyl, C_3-C_{12} cycloalkyl and C_3-C_{12} heterocyclyl;~~

~~wherein R^7 is absent when Y^1 is N or is selected from H, halogen, C_1-C_6 alkyl, C_1-C_6 heteroalkyl, C_3-C_{12} cycloalkyl, C_3-C_{12} heterocyclyl and C_1-C_6 alkoxy when Y^1 is C;~~

~~wherein R^8 is absent when Y^3 is N or is selected from H, halogen, C_1-C_6 alkyl, C_1-C_6 heteroalkyl, C_3-C_{12} cycloalkyl, C_3-C_{12} heterocyclyl and C_1-C_6 alkoxy when Y^3 is C;~~

~~wherein R^9 is absent when Y^2 is N or is selected from H, halogen, C_1-C_6 alkyl, C_3-C_{12} cycloalkyl, C_3-C_{12} heterocyclyl, C_1-C_6 alkoxy, C_1-C_6 heteroalkyl, C_0-C_3 alkylOC_0-C_3 alkyl aryl wherein the aryl is optionally substituted by NH_2, OC_1-C_6 alkyl, C_1-C_6 alkyl, C_1-C_6 heteroalkyl, halogen, CN, C_3-C_{12} cycloalkyl, C_3-C_{12} heterocyclyl; C_0-C_3~~

~~alkylOC$_0$-C$_3$ alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH$_2$, OC$_1$-C$_6$ alkyl, C$_1$-C$_6$ alkyl, C$_1$-C$_6$ heteroalkyl, halogen, CN, C$_3$-C$_{12}$ cycloalkyl, C$_3$-C$_{12}$ heterocyclyl; and C$_1$-C$_6$ alkyl substituted by aryl or heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH$_2$, OC$_1$-C$_6$ alkyl, C$_1$-C$_6$ alkyl, C$_1$-C$_6$ heteroalkyl, halogen, CN, C$_3$-C$_{12}$ cycloalkyl, C$_3$-C$_{12}$ heterocyclyl;~~

~~wherein R^{12} is selected from H, NH$_2$, NHC$_1$-C$_6$ alkyl, C$_1$-C$_6$ alkyl, C$_1$-C$_6$ heteroalkyl, C$_2$-C$_6$ alkenyl, C$_2$-C$_6$ alkynyl, C$_3$-C$_{12}$ cycloalkyl and C$_3$-C$_{12}$ heterocyclyl;~~

~~with the proviso that the compound of formula (I) is not 6 ([1,1' Biphenyl] 4 yloxy) pyridine 3 amine, 4 ([1,1' Biphenyl] 4 yloxy) aniline, 6 ([1,1' Biphenyl] 4 yloxy) 2 methylpyridin 3 amine and 6 ([1,1' Biphenyl] 4 yloxy) 4 methylpyridin 3 amine~~.

2. Use of the ~~The~~ compound of formula (I)



Formula (I)

pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof,

wherein X is selected from CH$_2$, CO, CHOH, CHO(C$_1$-C$_3$) alkyl, NH, and O;

wherein Y^1 is N and R^7 is absent, Y^2 is selected from N and C and Y^3 is C;

wherein Z is NR^{10}R^{11}, wherein R^{10} and R^{11} are each independently selected from H and C$_1$-C$_6$ alkyl;

wherein R^1 is selected from H, halogen, C$_1$-C$_6$ alkyl, C$_3$-C$_{12}$ cycloalkyl, C$_3$-C$_{12}$ heterocyclyl, C$_1$-C$_6$ alkoxy, C$_1$-C$_6$ heteroalkyl, C$_0$-C$_3$ alkylOC$_0$-C$_3$ alkyl aryl wherein the aryl is optionally substituted by NH$_2$, OC$_1$-C$_6$ alkyl, C$_1$-C$_6$ alkyl, C$_1$-C$_6$ heteroalkyl, halogen, CN, C$_3$-C$_{12}$ cycloalkyl, C$_3$-C$_{12}$ heterocyclyl; C$_0$-C$_3$ alkylOC$_0$-C$_3$ alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH$_2$, OC$_1$-C$_6$ alkyl, C$_1$-C$_6$ alkyl, C$_1$-C$_6$ heteroalkyl, halogen, CN, C$_3$-C$_{12}$ cycloalkyl, C$_3$-C$_{12}$ heterocyclyl; and C$_1$-C$_6$ alkyl substituted by aryl or heteroaryl wherein the aryl and the heteroaryl are

optionally substituted by NH_2, OC_1-C_6 alkyl, C_1-C_6 alkyl, C_1-C_6 heteroalkyl, halogen, CN, C_3-C_{12} cycloalkyl, C_3-C_{12} heterocyclyl;

wherein R^2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH_2, OC_1-C_6 alkyl, C_1-C_6 alkyl, C_1-C_6 heteroalkyl, halogen, CN, C_3-C_{12} cycloalkyl, C_3-C_{12} heterocyclyl, $C(O)R^{12}$, C_1-C_6 alkyl $C(O)R^{12}$;

wherein R^3 is selected from H, halogen, C_1-C_6 alkyl and C_3-C_{12} cycloalkyl;

wherein R^4 is selected from H and halogen and R^5 and R^6 are each independently selected from H and C_1-C_6 alkyl;

wherein R^8 is selected from H, halogen, C_1-C_6 alkyl and C_3-C_{12} cycloalkyl;

wherein R^9 is absent when Y^2 is N or is selected from H, halogen, C_1-C_6 alkyl and C_3-C_{12} cycloalkyl when Y^2 is C; and

wherein R^{12} is selected from NH_2, NHC_1-C_6 alkyl, C_1-C_6 alkyl, and C_1-C_6 heteroalkyl,

~~wherein X is selected from CH_2, CF_2, CHF, CO, CHOH, CHO(C_1-C_3) alkyl, NH, N(C_1-C_3 alkyl), S, SO and O;~~

~~wherein Y^1, Y^2, and Y^3 are each independently selected from N and C;~~

~~wherein Z is $NR^{10}R^{11}$, wherein R^{10} and R^{11} are each independently selected from H and C_1-C_6 alkyl;~~

~~wherein R^1 is selected from H, halogen, C_1-C_6 alkyl, C_3-C_{12} cycloalkyl, C_3-C_{12} heterocyclyl, C_1-C_6 alkoxy, C_1-C_6 heteroalkyl, C_0-C_3 alkylOC_0-C_3 alkyl aryl wherein the aryl is optionally substituted by NH_2, OC_1-C_6 alkyl, C_1-C_6 alkyl, C_1-C_6 heteroalkyl, halogen, CN, C_3-C_{12} cycloalkyl, C_3-C_{12} heterocyclyl; C_0-C_3 alkylOC_0-C_3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH_2, OC_1-C_6 alkyl, C_1-C_6 alkyl, C_1-C_6 heteroalkyl, halogen, CN, C_3-C_{12} cycloalkyl, C_3-C_{12} heterocyclyl; and C_1-C_6 alkyl substituted by aryl or heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH_2, OC_1-C_6 alkyl, C_1-C_6 alkyl, C_1-C_6 heteroalkyl, halogen, CN, C_3-C_{12} cycloalkyl, C_3-C_{12} heterocyclyl;~~

~~wherein R^2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH_2, OC_1-C_6 alkyl, C_1-C_6 alkyl, C_1-C_6 heteroalkyl, halogen, CN, C_3-C_{12} cycloalkyl, C_3-C_{12} heterocyclyl, $C(O)R^{12}$, C_1-C_6 alkyl $C(O)R^{12}$;~~

~~wherein R^3 is selected from H, halogen, C_1-C_6 alkyl, C_1-C_6 heteroalkyl, C_3-C_{12} cycloalkyl, C_3-C_{12} heterocyclyl and C_1-C_6 alkoxy;~~

~~wherein R^4, R^5 and R^6 are each independently selected from H, halogen, CN, C_1-C_6 alkoxy, C_1-C_6 S alkyl, C_1-C_6 alkyl, C_1-C_6 heteroalkyl, C_3-C_{12} cycloalkyl and C_3-C_{12} heterocyclyl;~~

~~wherein R^7 is absent when Y^1 is N or is selected from H, halogen, C_1-C_6 alkyl, C_1-C_6 heteroalkyl, C_3-C_{12} cycloalkyl, C_3-C_{12} heterocyclyl and C_1-C_6 alkoxy when Y^1 is C; wherein R^8 is absent when Y^3 is N or is selected from H, halogen, C_1-C_6 alkyl, C_1-C_6 heteroalkyl, C_3-C_{12} cycloalkyl, C_3-C_{12} heterocyclyl and C_1-C_6 alkoxy when Y^3 is C; wherein R^9 is absent when Y^2 is N or is selected from H, halogen, C_1-C_6 alkyl, C_3-C_{12} cycloalkyl, C_3-C_{12} heterocyclyl, C_1-C_6 alkoxy, C_1-C_6 heteroalkyl, C_0-C_3 alkylOC_0-C_3 alkyl aryl wherein the aryl is optionally substituted by NH_2, OC_1-C_6 alkyl, C_1-C_6 alkyl, C_1-C_6 heteroalkyl, halogen, CN, C_3-C_{12} cycloalkyl, C_3-C_{12} heterocyclyl; C_0-C_3 alkylOC_0-C_3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH_2, OC_1-C_6 alkyl, C_1-C_6 alkyl, C_1-C_6 heteroalkyl, halogen, CN, C_3-C_{12} cycloalkyl, C_3-C_{12} heterocyclyl; and C_1-C_6 alkyl substituted by aryl or heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH_2, OC_1-C_6 alkyl, C_1-C_6 alkyl, C_1-C_6 heteroalkyl, halogen, CN, C_3-C_{12} cycloalkyl, C_3-C_{12} heterocyclyl; wherein R^{12} is selected from H, NH_2, NHC_1-C_6 alkyl, C_1-C_6 alkyl, C_1-C_6 heteroalkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_{12} cycloalkyl and C_3-C_{12} heterocyclyl, for use in a method for the~~in the manufacture of a medicament for the treatment and/or prevention ~~or treatment~~ of cancer<u>s in a subject</u>.

3. A pharmaceutical composition comprising a compound of formula (I)



Formula (I)

pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof,

<u>wherein X is selected from CH_2, CO, CHOH, CHO(C_1-C_3) alkyl, NH, and O;</u>

<u>wherein Y^1 is N and R^7 is absent, Y^2 is selected from N and C and Y^3 is C;</u>

wherein Z is $NR^{10}R^{11}$, wherein R^{10} and R^{11} are each independently selected from H and C_1-C_6 alkyl;

wherein R^1 is selected from H, halogen, C_1-C_6 alkyl, C_3-C_{12} cycloalkyl, C_3-C_{12} heterocyclyl, C_1-C_6 alkoxy, C_1-C_6 heteroalkyl, C_0-C_3 alkylOC_0-C_3 alkyl aryl wherein the aryl is optionally substituted by NH_2, OC_1-C_6 alkyl, C_1-C_6 alkyl, C_1-C_6 heteroalkyl, halogen, CN, C_3-C_{12} cycloalkyl, C_3-C_{12} heterocyclyl; C_0-C_3 alkylOC_0-C_3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH_2, OC_1-C_6 alkyl, C_1-C_6 alkyl, C_1-C_6 heteroalkyl, halogen, CN, C_3-C_{12} cycloalkyl, C_3-C_{12} heterocyclyl; and C_1-C_6 alkyl substituted by aryl or heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH_2, OC_1-C_6 alkyl, C_1-C_6 alkyl, C_1-C_6 heteroalkyl, halogen, CN, C_3-C_{12} cycloalkyl, C_3-C_{12} heterocyclyl;

wherein R^2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH_2, OC_1-C_6 alkyl, C_1-C_6 alkyl, C_1-C_6 heteroalkyl, halogen, CN, C_3-C_{12} cycloalkyl, C_3-C_{12} heterocyclyl, $C(O)R^{12}$, C_1-C_6 alkyl $C(O)R^{12}$;

wherein R^3 is selected from H, halogen, C_1-C_6 alkyl and C_3-C_{12} cycloalkyl;

wherein R^4 is selected from H and halogen and R^5 and R^6 are each independently selected from H and C_1-C_6 alkyl;

wherein R^8 is selected from H, halogen, C_1-C_6 alkyl and C_3-C_{12} cycloalkyl;

wherein R^9 is absent when Y^2 is N or is selected from H, halogen, C_1-C_6 alkyl and C_3-C_{12} cycloalkyl when Y^2 is C; and

wherein R^{12} is selected from NH_2, NHC_1-C_6 alkyl, C_1-C_6 alkyl, and C_1-C_6 heteroalkyl

~~wherein X is selected from CH_2, CF_2, CHF, CO, CHOH, CHO(C_1-C_3) alkyl, NH, N(C_1-C_3 alkyl), S, SO and O;~~

~~wherein Y^1, Y^2, and Y^3 are each independently selected from N and C;~~

~~wherein Z is $NR^{10}R^{11}$, wherein R^{10} and R^{11} are each independently selected from H and C_1-C_6 alkyl;~~

~~wherein R^1 is selected from H, halogen, C_1-C_6 alkyl, C_3-C_{12} cycloalkyl, C_3-C_{12} heterocyclyl, C_1-C_6 alkoxy, C_1-C_6 heteroalkyl, C_0-C_3 alkylOC_0-C_3 alkyl aryl wherein the aryl is optionally substituted by NH_2, OC_1-C_6 alkyl, C_1-C_6 alkyl, C_1-C_6 heteroalkyl, halogen, CN, C_3-C_{12} cycloalkyl, C_3-C_{12} heterocyclyl; C_0-C_3 alkylOC_0-C_3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH_2, OC_1-C_6 alkyl, C_1-C_6 alkyl, C_1-C_6 heteroalkyl, halogen, CN, C_3-C_{12} cycloalkyl, C_3-C_{12} heterocyclyl; and C_1-C_6 alkyl substituted by aryl or heteroaryl wherein the aryl and the heteroaryl are~~

optionally substituted by NH_2, OC_1-C_6 alkyl, C_1-C_6 alkyl, C_1-C_6 heteroalkyl, halogen, CN, C_3-C_{12} cycloalkyl, C_3-C_{12} heterocyclyl;

wherein R^2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH_2, OC_1-C_6 alkyl, C_1-C_6 alkyl, C_1-C_6 heteroalkyl, halogen, CN, C_3-C_{12} cycloalkyl, C_3-C_{12} heterocyclyl, $C(O)R^{12}$, C_1-C_6 alkyl $C(O)R^{12}$;

wherein R^3 is selected from H, halogen, C_1-C_6 alkyl, C_1-C_6 heteroalkyl, C_3-C_{12} cycloalkyl, C_3-C_{12} heterocyclyl and C_1-C_6 alkoxy;

wherein R^4, R^5 and R^6 are each independently selected from H, halogen, CN, C_1-C_6 alkoxy, C_1-C_6 S alkyl, C_1-C_6 alkyl, C_1-C_6 heteroalkyl, C_3-C_{12} cycloalkyl and C_3-C_{12} heterocyclyl;

wherein R^7 is absent when Y^1 is N or is selected from H, halogen, C_1-C_6 alkyl, C_1-C_6 heteroalkyl, C_3-C_{12} cycloalkyl, C_3-C_{12} heterocyclyl and C_1-C_6 alkoxy when Y^1 is C;

wherein R^8 is absent when Y^3 is N or is selected from H, halogen, C_1-C_6 alkyl, C_1-C_6 heteroalkyl, C_3-C_{12} cycloalkyl, C_3-C_{12} heterocyclyl and C_1-C_6 alkoxy when Y^3 is C;

wherein R^9 is absent when Y^2 is N or is selected from H, halogen, C_1-C_6 alkyl, C_3-C_{12} cycloalkyl, C_3-C_{12} heterocyclyl, C_1-C_6 alkoxy, C_1-C_6 heteroalkyl, C_0-C_3 alkylOC_0-C_3 alkyl aryl wherein the aryl is optionally substituted by NH_2, OC_1-C_6 alkyl, C_1-C_6 alkyl, C_1-C_6 heteroalkyl, halogen, CN, C_3-C_{12} cycloalkyl, C_3-C_{12} heterocyclyl; C_0-C_3 alkylOC_0-C_3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH_2, OC_1-C_6 alkyl, C_1-C_6 alkyl, C_1-C_6 heteroalkyl, halogen, CN, C_3-C_{12} cycloalkyl, C_3-C_{12} heterocyclyl; and C_1-C_6 alkyl substituted by aryl or heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH_2, OC_1-C_6 alkyl, C_1-C_6 alkyl, C_1-C_6 heteroalkyl, halogen, CN, C_3-C_{12} cycloalkyl, C_3-C_{12} heterocyclyl;

wherein R^{12} is selected from H, NH_2, NHC_1-C_6 alkyl, C_1-C_6 alkyl, C_1-C_6 heteroalkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_{12} cycloalkyl and C_3-C_{12} heterocyclyl, and a pharmaceutically acceptable carrier.

4. The compound of formula (I) according to claim 1, the compound of formula (I) for use according to claim 2, and the pharmaceutical composition comprising a compound of formula (I) according to claim 3, wherein X is selected from CH_2, CO, CHOH, CHO(C_1-C_3) alkyl, NH, and O.

5. The compound of formula (I) according to claim 1, the compound of formula (I) for use according to claim 2, and the pharmaceutical composition comprising a compound of

formula (I) according to claim 3,

wherein X is selected from CH_2, CO, CHOH, CHO(C_1-C_3) alkyl, NH, and O;

wherein Y^1, Y^2, and Y^3 are each independently selected from N and C;

wherein Z is $NR^{10}R^{11}$, wherein R^{10} and R^{11} are each independently selected from H and C_1-C_6 alkyl;

wherein R^1 is selected from H, halogen, C_1-C_6 alkyl, C_3-C_{12} cycloalkyl, C_3-C_{12} heterocyclyl, C_1-C_6 alkoxy, C_1-C_6 heteroalkyl, C_0-C_3 alkylOC_0-C_3 alkyl aryl wherein the aryl is optionally substituted by NH_2, OC_1-C_6 alkyl, C_1-C_6 alkyl, C_1-C_6 heteroalkyl, halogen, CN, C_3-C_{12} cycloalkyl, C_3-C_{12} heterocyclyl; C_0-C_3 alkylOC_0-C_3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH_2, OC_1-C_6 alkyl, C_1-C_6 alkyl, C_1-C_6 heteroalkyl, halogen, CN, C_3-C_{12} cycloalkyl, C_3-C_{12} heterocyclyl; and C_1-C_6 alkyl substituted by aryl or heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH_2, OC_1-C_6 alkyl, C_1-C_6 alkyl, C_1-C_6 heteroalkyl, halogen, CN, C_3-C_{12} cycloalkyl, C_3-C_{12} heterocyclyl;

wherein R^2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH_2, OC_1-C_6 alkyl, C_1-C_6 alkyl, C_1-C_6 heteroalkyl, halogen, CN, C_3-C_{12} cycloalkyl, C_3-C_{12} heterocyclyl, $C(O)R^{12}$, C_1-C_6 alkyl $C(O)R^{12}$;

wherein R^3 is selected from H, halogen, C_1-C_6 alkyl and C_3-C_{12} cycloalkyl;

wherein R^4, R^5 and R^6 are each independently selected from H, halogen, CN, C_1-C_6 alkyl and C_1-C_6 heteroalkyl;

wherein R^7 is absent when Y^1 is N or is selected from H, halogen, C_1-C_6 alkyl and C_3-C_{12} cycloalkyl when Y^1 is C;

wherein R^8 is absent when Y^3 is N or is selected from H, halogen, C_1-C_6 alkyl and C_3-C_{12} cycloalkyl when Y^3 is C;

wherein R^9 is absent when Y^2 is N or is selected from H, halogen, C_1-C_6 alkyl and C_3-C_{12} cycloalkyl when Y^2 is C; and

wherein R^{12} is selected from NH_2, NHC_1-C_6 alkyl, C_1-C_6 alkyl, and C_1-C_6 heteroalkyl.

6. The compound of formula (I) according to claim 1, the compound of formula (I) for use according to claim 2, and the pharmaceutical composition comprising a compound of formula (I) according to claim 3,

wherein X is selected from CH_2, CO, CHOH, CHO(C_1-C_3) alkyl, NH, and O;

wherein Y^1 is N and R^7 is absent, Y^2 is selected from N and C and Y^3 is C;

wherein Z is $NR^{10}R^{11}$, wherein R^{10} and R^{11} are each independently selected from H and C_1-C_6 alkyl;

wherein R^1 is selected from H, halogen, C_1-C_6 alkyl, C_3-C_{12} cycloalkyl, C_3-C_{12} heterocyclyl, C_1-C_6 alkoxy, C_1-C_6 heteroalkyl, C_0-C_3 alkylOC_0-C_3 alkyl aryl wherein the aryl is optionally substituted by NH_2, OC_1-C_6 alkyl, C_1-C_6 alkyl, C_1-C_6 heteroalkyl, halogen, CN, C_3-C_{12} cycloalkyl, C_3-C_{12} heterocyclyl; C_0-C_3 alkylOC_0-C_3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH_2, OC_1-C_6 alkyl, C_1-C_6 alkyl, C_1-C_6 heteroalkyl, halogen, CN, C_3-C_{12} cycloalkyl, C_3-C_{12} heterocyclyl; and C_1-C_6 alkyl substituted by aryl or heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH_2, OC_1-C_6 alkyl, C_1-C_6 alkyl, C_1-C_6 heteroalkyl, halogen, CN, C_3-C_{12} cycloalkyl, C_3-C_{12} heterocyclyl;

wherein R^2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH_2, OC_1-C_6 alkyl, C_1-C_6 alkyl, C_1-C_6 heteroalkyl, halogen, CN, C_3-C_{12} cycloalkyl, C_3-C_{12} heterocyclyl, $C(O)R^{12}$, C_1-C_6 alkyl $C(O)R^{12}$;

wherein R^3 is selected from H, halogen, C_1-C_6 alkyl and C_3-C_{12} cycloalkyl;

wherein R^4, R^5 and R^6 are each independently selected from H, halogen, CN, C_1-C_6 alkyl and C_1-C_6 heteroalkyl;

wherein R^8 is selected from H, halogen, C_1-C_6 alkyl and C_3-C_{12} cycloalkyl;

wherein R^9 is absent when Y^2 is N or is selected from H, halogen, C_1-C_6 alkyl and C_3-C_{12} cycloalkyl when Y^2 is C; and

wherein R^{12} is selected from NH_2, NHC_1-C_6 alkyl, C_1-C_6 alkyl, and C_1-C_6 heteroalkyl.

7. The compound of formula (I) according to claim 1, the compound of formula (I) for use according to claim 2, and the pharmaceutical composition comprising a compound of formula (I) according to claim 3,

wherein X is selected from CH_2, CO, CHOH, CHO(C_1-C_3) alkyl, NH, and O;

wherein Y^1, Y^2, and Y^3 are each independently selected from N and C;

wherein Z is $NR^{10}R^{11}$, wherein R^{10} and R^{11} are each independently selected from H and C_1-C_6 alkyl;

wherein R^1 is selected from H, C_1-C_6 alkyl, C_0-C_3 alkylOC_0-C_3 alkyl aryl wherein the aryl is optionally substituted by NH_2; C_0-C_3 alkylOC_0-C_3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH_2;

~~wherein R^2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by OC_1-C_6 alkyl, C_1-C_6 alkyl, C_1-C_6 heteroalkyl, halogen, C_1-C_6 alkyl $C(O)R^{12}$;~~

~~wherein R^3 is H;~~

~~wherein R^4 is selected from H and halogen;~~

~~wherein R^5 and R^6 are each independently selected from H and C_1-C_6 alkyl;~~

~~wherein R^7 is absent when Y^1 is N or is H when Y^1 is C;~~

~~wherein R^8 is absent when Y^3 is N or is H when Y^3 is C;~~

~~wherein R^9 is absent when Y^2 is N or is H when Y^2 is C; and~~

~~wherein R^{12} is NH_2.~~

~~84~~. The compound of formula (I) according to claim 1, the use of the compound of formula (I) ~~for use~~ according to claim 2, and the pharmaceutical composition comprising a compound of formula (I) according to claim 3,

wherein X is selected from CH_2, CO, CHOH, CHO(C_1-C_3) alkyl, NH, and O;

wherein Y^1 is N and R^7 is absent, Y^2 is selected from N and C and Y^3 is C;

wherein Z is $NR^{10}R^{11}$, wherein R^{10} and R^{11} are each independently selected from H and C_1-C_6 alkyl;

wherein R^1 is selected from H, C_1-C_6 alkyl, C_0-C_3 alkylOC_0-C_3 alkyl aryl wherein the aryl is optionally substituted by NH_2; C_0-C_3 alkylOC_0-C_3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH_2;

wherein R^2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by OC_1-C_6 alkyl, C_1-C_6 alkyl, C_1-C_6 heteroalkyl, halogen, C_1-C_6 alkyl $C(O)R^{12}$;

wherein R^3 is H;

wherein R^4 is selected from H and halogen;

wherein R^5 and R^6 are each independently selected from H and C_1-C_6 alkyl;

wherein R^8 is H;

wherein R^9 is absent when Y^2 is N or is H when Y^2 is C; and

wherein R^{12} is NH_2.

~~95~~. The compound of formula (I) according to claim 1, the use of the compound of formula (I) ~~for use~~ according to claim 2, and the pharmaceutical composition comprising a compound of formula (I) according to claim 3,

wherein X is selected from CH_2, NH and O;

wherein Y^1 is N and R^7 is absent, Y^2 is selected from N and C and Y^3 is C~~wherein Y^1, Y^2, and Y^3 are each independently selected from N and C~~;

wherein Z is $NR^{10}R^{11}$, wherein R^{10} and R^{11} are each independently selected from H and C_1-C_6 alkyl;

wherein R^1 is selected from H, halogen, C_1-C_6 alkyl, C_3-C_{12} cycloalkyl, C_3-C_{12} heterocyclyl, C_1-C_6 alkoxy, C_1-C_6 heteroalkyl, C_0-C_3 alkylOC_0-C_3 alkyl aryl wherein the aryl is optionally substituted by NH_2, OC_1-C_6 alkyl, C_1-C_6 alkyl, C_1-C_6 heteroalkyl, halogen, CN, C_3-C_{12} cycloalkyl, C_3-C_{12} heterocyclyl; C_0-C_3 alkylOC_0-C_3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH_2, OC_1-C_6 alkyl, C_1-C_6 alkyl, C_1-C_6 heteroalkyl, halogen, CN, C_3-C_{12} cycloalkyl, C_3-C_{12} heterocyclyl; and C_1-C_6 alkyl substituted by aryl or heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH_2, OC_1-C_6 alkyl, C_1-C_6 alkyl, C_1-C_6 heteroalkyl, halogen, CN, C_3-C_{12} cycloalkyl, C_3-C_{12} heterocyclyl;

wherein R^2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH_2, OC_1-C_6 alkyl, C_1-C_6 alkyl, C_1-C_6 heteroalkyl, halogen, CN, C_3-C_{12} cycloalkyl, C_3-C_{12} heterocyclyl, $C(O)R^{12}$, C_1-C_6 alkyl $C(O)R^{12}$;

wherein R^3 is selected from H, halogen, C_1-C_6 alkyl and C_3-C_{12} cycloalkyl;

wherein R^4 is selected from H and halogen and R^5 and R^6 are each independently selected from H and C_1-C_6 alkyl~~R^4, R^5 and R^6 are each independently selected from H, halogen, CN, C_1-C_6 alkyl and C_1-C_6 heteroalkyl~~;

~~wherein R^7 is absent when Y^1 is N or is selected from H, halogen, C_1-C_6 alkyl and C_3-C_{12} cycloalkyl when Y^1 is C;~~

wherein R^8 is ~~absent when Y^3 is N or is~~ selected from H, halogen, C_1-C_6 alkyl and C_3-C_{12} cycloalkyl ~~when Y^3 is C~~;

wherein R^9 is absent when Y^2 is N or is selected from H, halogen, C_1-C_6 alkyl and C_3-C_{12} cycloalkyl when Y^2 is C; and

wherein R^{12} is selected from NH_2, NHC_1-C_6 alkyl, C_1-C_6 alkyl, and C_1-C_6 heteroalkyl.

~~106~~. The compound of formula (I) according to claim 1, the use of the compound of formula (I) ~~for use~~ according to claim 2, and the pharmaceutical composition comprising a compound of formula (I) according to claim 3,

wherein X is selected from CH_2, CO, CHOH, $CHO(C_1$-$C_3)$ alkyl, NH, and O;

wherein Y^1 is N and R^7 is absent, Y^2 is selected from N and C and Y^3 is C~~wherein Y^1, Y^2, and Y^3 are each independently selected from N and C~~;

wherein Z is $NR^{10}R^{11}$, wherein R^{10} and R^{11} are each independently selected from H and C_1-C_6 alkyl;

wherein R^1 is selected from H, halogen, C_1-C_6 alkyl, C_3-C_{12} cycloalkyl, C_3-C_{12} heterocyclyl, C_1-C_6 alkoxy and C_1-C_6 heteroalkyl;

wherein R^2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH_2, OC_1-C_6 alkyl, C_1-C_6 alkyl, C_1-C_6 heteroalkyl, halogen, CN, C_3-C_{12} cycloalkyl, C_3-C_{12} heterocyclyl, $C(O)R^{12}$, C_1-C_6 alkyl $C(O)R^{12}$;

wherein R^3 is selected from H, halogen, C_1-C_6 alkyl and C_3-C_{12} cycloalkyl;

wherein R^4 is selected from H and halogen and R^5 and R^6 are each independently selected from H and C_1-C_6 alkyl~~R^4, R^5 and R^6 are each independently selected from H, halogen, CN, C_1-C_6 alkyl and C_1-C_6 heteroalkyl~~;

~~wherein R^7 is absent when Y^1 is N or is selected from H, halogen, C_1-C_6 alkyl and C_3-C_{12} cycloalkyl when Y^1 is C;~~

wherein R^8 ~~is absent when Y^3 is N or~~ is selected from H, halogen, C_1-C_6 alkyl and C_3-C_{12} cycloalkyl ~~when Y^3 is C~~;

wherein R^9 is absent when Y^2 is N or is selected from H, halogen, C_1-C_6 alkyl and C_3-C_{12} cycloalkyl when Y^2 is C; and

wherein R^{12} is selected from NH_2, NHC_1-C_6 alkyl, C_1-C_6 alkyl, and C_1-C_6 heteroalkyl.

~~11~~7. The compound of formula (I) according to claim 1, the use of the compound of formula (I) ~~for use~~ according to claim 2, and the pharmaceutical composition comprising a compound of formula (I) according to claim 3,

wherein X is selected from CH_2, NH and O;

wherein Y^1 is N and R^7 is absent, Y^2 is selected from N and C and Y^3 is C~~wherein Y^1, Y^2, and Y^3 are each independently selected from N and C~~;

wherein Z is $NR^{10}R^{11}$, wherein R^{10} and R^{11} are each independently selected from H and C_1-C_6 alkyl;

wherein R^1 is selected from H, halogen, C_1-C_6 alkyl, C_3-C_{12} cycloalkyl, C_3-C_{12} heterocyclyl, C_1-C_6 alkoxy and C_1-C_6 heteroalkyl;

wherein R^2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH_2, OC_1-C_6 alkyl, C_1-C_6 alkyl, C_1-C_6 heteroalkyl, halogen, CN, C_3-C_{12} cycloalkyl, C_3-C_{12} heterocyclyl, $C(O)R^{12}$, C_1-C_6 alkyl $C(O)R^{12}$;

wherein R^3 is selected from H, halogen, C_1-C_6 alkyl and C_3-C_{12} cycloalkyl;

wherein R^4 is selected from H and halogen and R^5 and R^6 are each independently selected from H and C_1-C_6 alkyl~~R^4, R^5 and R^6 are each independently selected from H, halogen, CN, C_1-C_6 alkyl and C_1-C_6 heteroalkyl;~~

~~wherein R^7 is absent when Y^1 is N or is selected from H, halogen, C_1-C_6 alkyl and C_3-C_{12} cycloalkyl when Y^1 is C;~~

wherein R^8 ~~is absent when Y^3 is N or~~ is selected from H, halogen, C_1-C_6 alkyl and C_3-C_{12} cycloalkyl~~ when Y^3 is C~~;

wherein R^9 is absent when Y^2 is N or is selected from H, halogen, C_1-C_6 alkyl and C_3-C_{12} cycloalkyl when Y^2 is C; and

wherein R^{12} is selected from NH_2, NHC_1-C_6 alkyl, C_1-C_6 alkyl, and C_1-C_6 heteroalkyl.

~~12. The compound of formula (I) according to claim 1, the compound of formula (I) for use according to claim 2, and the pharmaceutical composition comprising a compound of formula (I) according to claim 3,~~

~~wherein X is selected from CH_2, CO, CHOH, CHO(C_1-C_3) alkyl, NH, and O;~~

~~wherein Y^1, Y^2, and Y^3 are each independently selected from N and C;~~

~~wherein Z is $NR^{10}R^{11}$, wherein R^{10} and R^{11} are each independently selected from H and C_1-C_6 alkyl;~~

~~wherein R^1 is selected from H and C_1-C_6 alkyl;~~

~~wherein R^2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by OC_1-C_6 alkyl, C_1-C_6 alkyl, C_1-C_6 heteroalkyl, halogen, C_1-C_6 alkyl C(O)R^{12};~~

~~wherein R^3 is H;~~

~~wherein R^4 is selected from H and halogen;~~

~~wherein R^5 and R^6 are each independently selected from H and C_1-C_6 alkyl;~~

~~wherein R^7 is absent when Y^1 is N or is H when Y^1 is C;~~

~~wherein R^8 is absent when Y^3 is N or is H when Y^3 is C;~~

~~wherein R^9 is absent when Y^2 is N or is H when Y^2 is C; and~~

~~wherein R^{12} is NH_2.~~

~~13~~8. The compound of formula (I) according to claim 1, the use of the compound of formula (I) ~~for use~~ according to claim 2, and the pharmaceutical composition comprising a

compound of formula (I) according to claim 3,

wherein X is selected from CH_2, CO, CHOH, CHO(C_1-C_3) alkyl, NH, and O;

wherein Y^1 is N and R^7 is absent, Y^2 is selected from N and C and Y^3 is C;

wherein Z is $NR^{10}R^{11}$, wherein R^{10} and R^{11} are each independently selected from H and C_1-C_6 alkyl;

wherein R^1 is selected from H and C_1-C_6 alkyl;

wherein R^2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by OC_1-C_6 alkyl, C_1-C_6 alkyl, C_1-C_6 heteroalkyl, halogen, C_1-C_6 alkyl $C(O)R^{12}$;

wherein R^3 is H;

wherein R^4 is selected from H and halogen;

wherein R^5 and R^6 are each independently selected from H and C_1-C_6 alkyl;

wherein R^8 is H;

wherein R^9 is absent when Y^2 is N or is H when Y^2 is C; and

wherein R^{12} is NH_2.

~~149~~. The compound of formula (I) according to claim 1, the use of the compound of formula (I) ~~for use~~ according to claim 2, and the pharmaceutical composition comprising a compound of formula (I) according to claim 3,

wherein X is selected from CH_2, CO, CHOH, CHO(C_1-C_3) alkyl, NH, and O;

wherein Y^1 is N and R^7 is absent, Y^2 is selected from N and C and Y^3 is C~~wherein Y^1, Y^2, and Y^3 are each independently selected from N and C~~;

wherein Z is $NR^{10}R^{11}$, wherein R^{10} and R^{11} are each independently selected from H and C_1-C_6 alkyl;

wherein R^1 is selected from C_0-C_3 alkylOC_0-C_3 alkyl aryl wherein the aryl is optionally substituted by NH_2, OC_1-C_6 alkyl, C_1-C_6 alkyl, C_1-C_6 heteroalkyl, halogen, CN, C_3-C_{12} cycloalkyl, C_3-C_{12} heterocyclyl; and C_0-C_3 alkylOC_0-C_3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH_2, OC_1-C_6 alkyl, C_1-C_6 alkyl, C_1-C_6 heteroalkyl, halogen, CN, C_3-C_{12} cycloalkyl, C_3-C_{12} heterocyclyl;

wherein R^2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH_2, halogen, C_1-C_6 alkyl, CN;

wherein R^3 is selected from H, halogen and C_1-C_4 alkyl;

wherein R^4, R^5 and R^6 are each independently selected from H, halogen, and C_1-C_4 alkyl;

~~wherein R^7 is absent when Y^1 is N or is selected from H, halogen and C_1-C_4 alkyl when Y^1 is C;~~

wherein R^8 ~~is absent when Y^3 is N or~~ is selected from H, halogen and C_1-C_4 alkyl ~~when Y^3 is C~~; and

wherein R^9 is absent when Y^2 is N or is selected from H, halogen and C_1-C_4 alkyl when Y^2 is C.

~~15. The compound of formula (I) according to claim 1, the compound of formula (I) for use according to claim 2, and the pharmaceutical composition comprising a compound of formula (I) according to claim 3,~~

~~wherein X is selected from CH_2, NH and O, and is preferably O;~~

~~wherein Y^1, Y^2, and Y^3 are each independently selected from N and C;~~

~~wherein Z is $NR^{10}R^{11}$, wherein R^{10} and R^{11} are each independently selected from H and C_1-C_6 alkyl;~~

~~wherein R^1 is selected from C_0-C_3 alkylOC_0-C_3 alkyl aryl wherein the aryl is optionally substituted by NH_2, OC_1-C_6 alkyl, C_1-C_6 alkyl, C_1-C_6 heteroalkyl, halogen, CN, C_3-C_{12} cycloalkyl, C_3-C_{12} heterocyclyl; and C_0-C_3 alkylOC_0-C_3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH_2, OC_1-C_6 alkyl, C_1-C_6 alkyl, C_1-C_6 heteroalkyl, halogen, CN, C_3-C_{12} cycloalkyl, C_3-C_{12} heterocyclyl;~~

~~wherein R^2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH_2, halogen, C_1-C_6 alkyl, CN;~~

~~wherein R^3 is selected from H, halogen and C_1-C_4 alkyl;~~

~~wherein R^4, R^5 and R^6 are each independently selected from H, halogen, and C_1-C_4 alkyl;~~

~~wherein R^7 is absent when Y^1 is N or is selected from H, halogen and C_1-C_4 alkyl when Y^1 is C;~~

~~wherein R^8 is absent when Y^3 is N or is selected from H, halogen and C_1-C_4 alkyl when Y^3 is C; and~~

~~wherein R^9 is absent when Y^2 is N or is selected from H, halogen and C_1-C_4 alkyl when Y^2 is C.~~

~~16. The compound of formula (I), the compound of formula (I) for use, and the pharmaceutical composition comprising a compound of formula (I) according to anyone of~~

~~claims 1 to 15, wherein X is selected from CH_2, CO, CHOH, CHO(C_1-C_3) alkyl, and O.~~

~~17. The compound of formula (I), the compound of formula (I) for use, and the pharmaceutical composition comprising a compound of formula (I) according to anyone of claims 1 to 15, wherein X is CH_2 or O.~~

~~18. The compound of formula (I), the compound of formula (I) for use, and the pharmaceutical composition comprising a compound of formula (I) according to anyone of claims 1 to 15, wherein X is O.~~

~~19~~10. The compound of formula (I) according to claim 1 or 5, the use of the compound of formula (I) ~~for use~~ according to claim 2 or 5, and the pharmaceutical composition comprising a compound of formula (I) according to according to claim 3 or 5~~anyone of claims 1 to 6, 9 and 16 to 18~~, wherein R^1 is selected from H, halogen, C_1-C_6 alkyl, C_1-C_6 heteroalkyl, C_0-C_3 alkylOC_0-C_3 alkyl aryl wherein the aryl is optionally substituted by NH_2, C_1-C_6 alkyl, C_1-C_6 heteroalkyl, halogen, CN, preferably is optionally substituted by NH_2; and C_0-C_3 alkylOC_0-C_3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH_2, OC_1-C_6 alkyl, C_1-C_6 alkyl, C_1-C_6 heteroalkyl, halogen, CN, C_3-C_{12} cycloalkyl, C_3-C_{12} heterocyclyl, preferably is optionally substituted by NH_2.

~~20~~11. The compound of formula (I) according to any one of claims 1 and 4-10, the use of the compound of formula (I) according to any one of claims 2 and 4-10~~for use~~, and the pharmaceutical composition comprising a compound of formula (I) according to any one of claims ~~1 to 19~~3 and 4-10, wherein R^2 is selected from aryl and heteroaryl, wherein the aryl is a phenyl group which is optionally substituted, wherein the optional substitution of the phenyl group is in meta or para position, preferably in para position.

~~21. The compound of formula (I), the compound of formula (I) for use, and the pharmaceutical composition comprising a compound of formula (I) according to anyone of claims 1 to 6, 9 to 11 and 16 to 19, wherein R^2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH_2, C_1-C_6 alkyl, C_1-C_6 heteroalkyl, halogen, CN, $C(O)R^{12}$, C_1-C_6 alkyl $C(O)R^{12}$.~~

~~22. The compound of formula (I), the compound of formula (I) for use, and the pharmaceutical composition comprising a compound of formula (I) according to anyone of claims 1 to 6, 9 to11 and 16 to 21, wherein R^3 is selected from H, halogen and C_1-C_4 alkyl, preferably is H and/or~~

~~wherein R^4, R^5 and R^6 are each independently selected from H, halogen, CN, C_1-C_6 alkyl and C_1-C_6 heteroalkyl.~~

~~23. The compound of formula (I), the compound of formula (I) for use, and the pharmaceutical composition comprising a compound of formula (I) according to anyone of claims 1 to 5, 7, 9 to 12, and 14 to 22 wherein R^7 is absent when Y^1 is N or is selected from H, halogen and C_1-C_4 alkyl, preferably selected from H, halogen, and methyl when Y^1 is C;~~

~~wherein R^8 is absent when Y^3 is N or is selected from H, halogen and C_1-C_4 alkyl preferably selected from H, halogen, and methyl when Y^3 is C;~~

~~wherein R^9 is absent when Y^2 is N or is selected from H and C_1-C_4 alkyl preferably selected from H, halogen, and methyl when Y^2 is C; and/or~~

~~wherein R^{10} is H; and R^{11} is selected from H and C_1-C_4 alkyl, preferably is H or methyl.~~

~~24. The compound of formula (I), the compound of formula (I) for use, and the pharmaceutical composition comprising a compound of formula (I) according to anyone of claims 1 to 4, wherein R^{12} is selected from NH_2, NHC_1-C_6 alkyl, C_1-C_6 alkyl, and C_1-C_6 heteroalkyl.~~

~~25. The compound of formula (I), the compound of formula (I) for use, and the pharmaceutical composition comprising a compound of formula (I) according to anyone of claims 1 to 5, 7, 9 to 12 and 14 to 22, wherein Y^1 is N and R^7 is absent.~~

~~26. The compound of formula (I), the compound of formula (I) for use, and the pharmaceutical composition comprising a compound of formula (I) according to anyone of claims 1 to 5, 7, 9 to 12 and 14 to 22, wherein Y^1 is N and R^7 is absent, Y^2 is selected from N and C and Y^3 is C.~~

~~27~~12. The compound of formula (I) according to any one of claims 1 and 4-10, the use of the compound of formula (I) according to any one of claims 2 and 4-10~~for use~~, and/or the pharmaceutical composition comprising a compound of formula (I) according to any one of

claims 3 and 4-10~~1 to 26~~, wherein R^2 is selected from aryl and heteroaryl wherein the heteroaryl is an optionally substituted aromatic 5-, or 6- membered monocyclic group.

~~28. The compound of formula (I) according to anyone of claims 1 to 27, wherein R^2 is selected from aryl and heteroaryl, with the proviso that the heteroaryl is not unsubstituted thiazole, oxazole, imidazole and pyrrole.~~

~~29. The compound of formula (I), the compound of formula (I) for use, and/or the pharmaceutical composition comprising a compound of formula (I) according to anyone of claims 1 to 28 with the proviso that the compound of formula (I) is not 4-(4'-Methoxy-biphenyl-4-yloxy)phenylamine, 4-(4'-Chloro-biphenyl-4-yloxy)phenylamine, 4-(4'-*tert*-Butyl-biphenyl-4-yloxy)phenylamine.~~

~~30. The compound of formula (I), the compound of formula (I) for use, and/or the pharmaceutical composition comprising a compound of formula (I) according to anyone of claims 1 to 29 with the proviso that the compound of formula (I) is not 4-(4-(thiazol-2-yl)phenoxy)aniline, 4-(4-(1*H*-imidazol-2-yl)phenoxy)aniline, 4-(4-(oxazol-2-yl)phenoxy)aniline and 4-(4-(1*H*-pyrrol-1-yl)phenoxy)aniline.~~

~~31. The compound of formula (I) for use and/or the pharmaceutical composition comprising a compound of formula (I) according to anyone of claims 2 to 30, with the proviso that the compound of formula (I) is not 4-([1,1'-Biphenyl]-4-yloxy)-aniline.~~

~~32. The compound of formula (I), the compound of formula (I) for use, and/or the pharmaceutical composition comprising a compound of formula (I) according to anyone of claims 2 to 30 with the proviso that the compound of formula (I) is not 6-([1,1'-Biphenyl]-4-yloxy)-pyridine-3-amine, 4-([1,1'-Biphenyl]-4-yloxy)-aniline, 6-([1,1'-Biphenyl]-4-yloxy)-2-methylpyridin-3-amine and 6-([1,1'-Biphenyl]-4-yloxy)-4-methylpyridin-3-amine.~~

~~33~~13. The compound of formula (I) according to claim 1, the use of the compound of formula (I) ~~for use~~ according to claim 2, and/or the pharmaceutical composition comprising a compound of formula (I) according to claim 3, selected from the group consisting of

	
	
	
	
	
	
	
	

	
	
	
	
	
	
	
	

	
	
	
	
	
	
	

	
	
	
	
	

~~34~~14. The use of the compound of formula (I)~~) for use~~ according to claim 2, selected from the group consisting of

	

	
	
	
	
	
	
	
	
	

	
	
	
	
	
	
	
	

	
	
	
	
	
	

	
	
	
	
	
	

35~~15~~. The compound of formula (I) according to claim 1, the use of the compound of formula (I) ~~for use~~ according to claim 2, and/or the pharmaceutical composition comprising a

compound of formula (I) according to claim 3, selected from the group consisting of

	
	
	
	
	
	
	
	

~~36~~16. The use of the compound of formula (I) ~~for use~~ according to any one of claims 2 and 4-15~~to 27, and 29 to 35~~, wherein the cancer is a Notch dependent cancer.